As the 340B Drug Pricing Program (“340B program”) has expanded in size and complexity, covered entities have looked externally for assistance in managing and growing their use of the program. This has created the opportunity for vendor firms to enter the 340B space. The compensation earned by 340B vendors has made them a target for investors, including corporations, private equity firms, and venture capitalists. Since 2002, according to review of public data sets and company disclosures, more than sixty significant transactions have involved private, for-profit companies active in the 340B space. The last three years alone have seen at least thirteen transactions, including two investments of more than $1 billion.
Read the full article: Private Equity and Corporate Investment Activity in 340B //
Source: https://media.thinkbrg.com/wp-content/uploads/2024/08/26130312/340B_Private-Equity-and-Corporate-Investment-Activity_2024.pdf